medigraphic.com
ISSN 1561-3186 (Electronic)

2015, Number 2

<< Back Next >>

Rev Acta Médica 2015; 16 (2)

Nonalcoholic fatty liver and its association with resistance to insulin and carotidal vascular damage

Calderín BRO, Pérez BLÁ, Domínguez ÁC, Velbes MPE, Yanes QM, Yanes QMÁ

Language: Spanish
References: 54
Page:
PDF size: 218.04 Kb.


ABSTRACT

Objective: to determine whether there is any association between the presence of nonalcoholic fatty liver and the resistance to insulin and carotidal vascular damage.
Method: a descriptive and cross-sectional study was carried out with 75 patients at ages between 18 and 75 years who had consecutively been performed liver biopsy at Hermanos Ameijeiras Hospital.
Results: nonalcoholic fatty liver with resistance to insulin was present in 25 patients (78.12%), and without resistance to insulin in 7 patients (21.88%), while the group without nonalcoholic fatty liver presented 18 patients (41.86%) with resistance to insulin and 25 patients (58.14%) without resistance to insulin (p=0.001, P=0.000). Carotidal vascular damage was observed in patients with nonalcoholic fatty liver and resistance to insulin in 21 patients (84%), while in the group of patients without nonalcoholic fatty liver and with resistance to insulin carotidal vascular damage was present in 4 patients (16%).
Conclusions: nonalcoholic fatty liver is associated with resistance to insulin and carotidal vascular damage.


REFERENCES

  1. Calderín Bouza RO, Domínguez Álvarez C, Velbes Marquetti PE, Pérez Blanco LA, Cabrera Rode E, Orlandi González N. Insulinorresistencia e hígado graso no alcohólico. ¿Existe relación causa-efecto entre ambas condiciones? Rev Cubana de Endocrinol. 2009;20:1-20.

  2. Moreno D. Avances en hígado graso no alcohólico. Med Clin (Barc). 2009;133:258-60.

  3. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372-84.

  4. Wasada T, Kasahara T, Wada J, Jimba S, Fujimaki R, Nakagami T, et al. Hepatic steatosis rather than visceral adiposity is more closely associated with insulin resistance in the early stage of obesity. Metabolism. 2008;57:980-5.

  5. Van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology. 2008;48:449-57.

  6. Ardigo D, Numeroso F, Valtuena S, Franzini L, Piatti PM, Monti L, et al. Hyperinsulinemia predicts hepatic fat content in healthy individuals with normal transaminase concentrations. Metabolism. 2005;54:1566-70.

  7. Gambino R, Cassader M, Pagano G, Durazzo M, Musso G. Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH? Curr Med Chem. 2007;14:1988-99.

  8. Méndez Sánchez N, Chávez Tapia NC, Zamora Valdés D, Medina Santillán R, Uribe M. Hepatobiliary diseases and insulin resistance. Hepatology. 2007;45:1097-107.

  9. Pérez Aguilar F, Benlloch S, Berenger M, Beltrán B, Berenguer J. Esteatohepatitis no alcohólica: consideraciones fisiopatológicas, clínicas y terapéuticas. Rev Esp Enferm Dig. 2004;96:1-22.

  10. Ludwing J, Viffiana TR, McGill DB, Ott BJ. Non-alcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-8.

  11. Calderín Bouza RO, Orlandi González N. Síndrome metabólico vs. síndrome de insulinorresistencia. Diferentes términos, clasificaciones y enfoques: ¿Existe o no? Rev Cubana Endocrinol. 2006;17:1-9.

  12. Calderín Bouza RO, Prieto Fernández M, Cabrea Rode E. Síndrome de insulinorresistencia en niños y adolescentes. Rev Cubana Endocrinol. 2007;18:1-14.

  13. Yanes Quesada MA, Yanes Quesada M, Calderín Bouza R, Cruz Hernández J. Síndrome de insulinorresistencia, una amenaza para la salud. Rev Cubana Endocrinol. 2008;19:1-5

  14. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich Y, et-al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7:234-8.

  15. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of nonalcoholic fatty liver disease (NAFLD) and diagnostic accuracy of noninvasive tests for liver disease severity. Ann Med. 2011;43:617-49.

  16. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan H, et-al. Disease progression of nonalcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010;59:969-74.

  17. Bedogni G, Belletani S. Fatty liver: How frequent is it and why? Ann Hepatol. 2004;3:63-5.

  18. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-331.

  19. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010-2030. Diabetes Res Clin Pract. 2010;87:4-14.

  20. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et-al. Nonalcoholic fatty liver disease, steatohepatitis and the metabolic syndrome. Hepatology. 2003;37:917-23.

  21. Lazo M, Clark JM. The epidemiology of non-alcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008;28:339-50.

  22. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the dionysos nutrition and liver study. Hepatology. 2005;42:44-52.

  23. Assy N, Djibre A, Farah R, Grosovski M, Marmor A. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology. 2010;254:393-400.

  24. Björnsson E. The clinical aspects of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol. 2008;54:7-18.

  25. Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol. 2008;49:600-7.

  26. Lizardi Cervera J, Aguilar Zapata D. Nonalcoholic fatty liver disease and its association with cardiovascular disease. Ann Hepatol. 2009;8 Suppl 1:S40-3.

  27. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30:1212-8.

  28. Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 2008;51:444-50.

  29. Targher G, Bertolini L, Padovani R, Poli F, Scala L, Zenari L, et al. Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients. J Endocrinol Invest. 2006;29:55-60.

  30. Karakurt F, Carlioglu A, Koktener A, Ozbek M, Kaya A, Uyar ME, et al. Relationship between cerebral arterial pulsatility and carotid intima media thickness in diabetic and non-diabetic patients with non-alcoholic fatty liver disease. J Endocrinol Invest. 2009;32:63-8.

  31. Brea A, Mosquera D, Martín E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol. 2005;25:1045-50.

  32. Adams LA, Angulo P. Recent concepts en Non-alcoholic fatty liver disease. Diabet Med. 2005;22:1129-33.

  33. Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol. 2007;102:399-408.

  34. McCullough AJ. Update on non-alcoholic fatty liver disease. J Clin Gastroenterol. 2002;34:55-62.

  35. Moreno Sánchez D. Epidemiología e historia natural de la hepatopatía grasa no alcohólica primaria. Gastroenterol Hepatol. 2006;29:244-54.

  36. Kleiner DE, Brunt EM, Van Natta M, Behlinh C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-21.

  37. Standards of medical care in diabetes. Diabetes Care. 2014;37:s14-s80.

  38. Alberti KGMM, Zimmet Pz. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med. 1998;15:539-53.

  39. Ascaso JF, Romero P, Real JT, Priego A, Valdecabres C, Carmena R. Cuantificación de insulinorresistencia con los valores de insulina basal e índice HOMA en una población no diabética. Med Clin (Barc). 2001;117:530-3.

  40. Stern SE, Williams K, Ferrannini E, DeFronzo RA, Bogardus C, Stern MP. Identification of individual with insulin resistance using routine clinical measurement. Diabetes. 2005;54:333-9.

  41. Blomgarden ZT. Measures of insulin sensivity. Clin Lab Med. 2006;26:611-33.

  42. Fronzo R de, Tobin J, Andrés R. Glucosa clamp technique: a method for the quantification of beta cell sensitivity to glucose and of tissue sensitivity to insulin. Am J Physiol. 1979;237:214-23.

  43. Bergman R. Toward physiological understanding of glucose tolerance: minimal model approach. Diabetes. 1989;38:1527.

  44. Harano Y, Ohgaku S, Hidaka H, Haneda K, Kikkawa R, Shigela Y, et al. Glucosa insulin and somatostatin infusions for measurement of in vivo insulin resistance. J Clin Endocrinol Metab. 1977;45:1124-7.

  45. Ferannini E, Mari A. How to measure insulin sensitivity. J Hypertens. 1998;16:895-906.

  46. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.

  47. Hosker JP, Matthews DR, Rudenski AS, Naylor BA, Teacher DF, Turner RC. Homeostasis model assessment: insulin resistance and Beta cell function from fatting plasma and insulin concentration in man. Diabetologia. 1985;28:401-11.

  48. Martínez de Morentin BE, Rodríguez MC, Martínez JA. Síndrome metabólico, resistencia a la insulina y metabolismo celular. Endocrinol Nutr. 2003;50:324-33.

  49. Hrebicek J, Janout V, Malincikova J, Horakova D, Cizek L. Detection of insulin resistance by simple quantitative insulin sensitivity check index QUICKI for epidemiological assessment and prevention. J Clin Endocrinol Metab. 2002;87:144-7.

  50. Soonthornpun S, Setasuban W, Thamprasit A, Chayanunnukul W, Rattarasarn C, Geater A. Novel insulin sensitivity index derived from oral glucose tolerance test. J Clin Endocrinol Metab. 2003;88:1019-23.

  51. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implication. Hepatology. 2010;51:679-89.

  52. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132:2169-72.

  53. Choi SY, Kim D, Kang JH, Park MJ, Kim YS, Lim SH, et al. Nonalcoholic fatty liver disease as a risk factor of cardiovascular disease: relation of non-alcoholic fatty liver disease to carotid atherosclerosis. Korean J Hepatol. 2008;14:77-88.

  54. Piñeiro Lamas R, Fernández-Britto Rodriguez JE. Hígado graso no alcohólico como señal de aterosclerosis. Rev Cubana Invest Bioméd. 2013;32:1-12.




2020     |     www.medigraphic.com